AN9025 Key Features - AN9025 is a novel pan-RAS(ON) inhibitor developed by Adlai Nortye with improved potency and a favorable PK/PD profile[8, 16] - AN9025 strongly binds to cyclophilin A (CypA) with a dissociation constant (KD1) of 3.2 nM, exhibiting a 4-fold stronger binding affinity compared to RMC-6236[3, 4, 8] - AN9025 exhibits a 3- to 8-fold higher binding affinity for tri-complex formation compared to RMC-6236[5] - AN9025 demonstrates approximately 100-fold greater potency in inhibiting cell viability across RAS-mutant cell lines compared to RMC-6236[8] - AN9025 shows potent anti-proliferative activity in RAS-addicted cancer cell lines with picomolar IC50 values[7, 8] In Vivo Efficacy and PK/PD - In vivo studies show that AN9025 induces deep tumor regression, with efficacy comparable to or exceeding RMC-6236 in mouse CDX models[8, 9] - AN9025 demonstrates a favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile in vivo[8] - AN9025 exhibits more sustained DUSP6 inhibition compared to RMC-6236 across all tested doses[8] Clinical Development - The prolonged tumor DUSP6 suppression following AN9025 administration suggests the potential for an intermittent dosing regimen to optimize tolerability and efficacy[8] - AN9025 is advancing through the IND-enabling stage[8] - Adlai Nortye is actively seeking strategic partnerships to advance the development of AN9025[18]

REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS- addicted cancers and Summit Therapeutics, Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into ...

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhi ...

Core Insights - Zoldonrasib, a RAS(ON) G12D-selective inhibitor, shows acceptable tolerability and promising initial antitumor activity in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Data - New clinical data for zoldonrasib was presented at the American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential as a treatment for NSCLC [1][2] - The Phase 1 study (RMC-9805-001) involved 90 solid tumor patients treated with 1200 mg once daily, demonstrating an acceptable safety profile consistent with previous data in pancreatic cancer [3] - The most common treatment-related adverse events (TRAEs) included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%), primarily Grade 1 or 2 in severity [3] Group 2: Efficacy Results - Preliminary antitumor activity was assessed in 18 efficacy-evaluable NSCLC patients, showing an objective response rate of 61% (11 patients) and a disease control rate of 89% (16 patients) [4] - The data indicates a high unmet need for new treatments in this patient population, as there are currently no approved targeted therapies for RAS G12D mutant cancers [5] Group 3: Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [6] - The company is advancing zoldonrasib as a monotherapy and in combination therapies, aiming to provide innovative treatment options for hard-to-treat cancers [2][6]

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [2] - The company is participating in two upcoming investor conferences, indicating active engagement with the investment community [1][3] Company Overview - Revolution Medicines specializes in RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [2] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), all of which are in clinical development [2] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [2] - Additional pipeline opportunities include RMC-0708 (Q61H) and RMC-8839 (G13C), focusing on RAS(ON) mutant-selective inhibitors [2] Upcoming Events - The company will participate in the Needham 24 Annual Virtual Healthcare Conference on April 7 at 2:15 p.m. ET [3] - Additionally, Revolution Medicines will be part of the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 1:00 p.m. ET [3]